NCT00262860View on ClinicalTrials.gov

Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

May 31, 2008

Conditions
Lymphoma
Interventions
DRUG

bortezomib

DRUG

gemcitabine hydrochloride

Trial Locations (2)

14642

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

University of Rochester

OTHER

NCT00262860 - Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter